Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation by Espinosa, Marta et al.
CASE REPORT Open Access
Advanced sporadic renal epithelioid
angiomyolipoma: case report of an
extraordinary response to sirolimus linked
to TSC2 mutation
Marta Espinosa1, Juan Maria Roldán-Romero2, Ignacio Duran1,3*†, Enrique de Álava4, María Apellaniz-Ruiz2,
Alberto Cascón2,5, Carmen Garrigos3, Mercedes Robledo2,5 and Cristina Rodriguez-Antona2,5*†
Abstract
Background: Renal epithelioid angiomyolipomas (EAML) are rare tumors with aggressive behavior. EAML can be
sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of TSC1 or TSC2 genes
(critical negative regulators of mTOR Complex 1) result in an increased activation of mTOR pathway. Optimal EAML
treatment, including mTOR inhibitors, remains undetermined.
Case presentation: Here we present the case of a young adult with a renal EAML that after radical nephrectomy
developed metastases, first in liver and then in lumbar vertebrae. After complete surgical resection of these lesions,
liver recurrence was detected, this time with incomplete surgical resection. After finding a new liver lesion, systemic
treatment with sirolimus started. The patient exhibited a complete and durable response to this drug, being disease
free at the time of publication, after 36 months of treatment. Targeted next generation sequencing (NGS) of MTOR,
TSC1 and TSC2 genes in the primary tumor, metastasis and blood of the patient, revealed one inactivating TSC2
mutation (c.2739dup; p.K914*) in the tumor cells. Immunohistochemistry revealed decreased TSC2 protein content
and increased phospho-S6 in the tumor cells, demonstrating mTOR pathway activation.
Conclusion: NGS on an EAML patient with an extraordinary response to sirolimus uncovered TSC2 inactivation as
the mechanism for the response. This study supports NGS as a useful tool to identify patients sensitive to mTOR
inhibitors and supports the treatment of malignant EAML with these drugs.
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Background
Angiomyolipomas (AML) are rare kidney tumors that
occur in 0.2–0.3% of the population [1, 2]. These neo-
plasms are mesenchymal in origin and comprise blood
vessels, mature adipose tissue and fusiform cells similar to
smooth muscle. Depending on the major component,
AML is histologically classified into fat-predominant,
smooth muscle-predominant, epithelioid, oncocytic and
sclerosant subtype [3]. Most AMLs are considered benign
and have a primarily local growth. However, one particular
subtype characterized by the presence of an epithelioid
cellular morphology, named epithelioid AML (EAML),
and included in the family of perivascular epithelioid cell
tumors (PEComas) can have malignant behaviour [4, 5].
Histologically, EAML cells contain granular cytoplasm in
more than 5% of tumor volume, with round nucleus and
occasional multinucleated giant cells dispersed. They can
co-express melanocytic and muscle markers and are nega-
tive for epithelial markers. The low percentage of fat is
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characteristic of this variety of AML and makes diagnosis
difficult with CT or MRI.
The behaviour of EAML is variable, ranging from indo-
lent, with only local growth, to aggressive, with potential for
invasive growth and dissemination. This different behaviour
seems to be determined by the presence or absence of cel-
lular atypia and other clinical and pathological factors. The
definition of atypical epithelioid cells in series of EAML in-
cludes atypical polygonal cells with abundant cytoplasm,
vesicular nuclei, prominent nucleoli and nuclear size that
exceeds twice the size of the adjacent nuclei. In a compara-
tive analysis of the literature published by Brimo et al., 21
EAML cases with benign clinical course were compared
with 9 EAML with malignant behaviour [6]. The aggressive
cases tended to associate with older patients, larger tumor
size, higher percentage of epithelioid component, severe
atypia, higher percentage of atypical cells, higher mitotic
count, atypical mitotic figures, necrosis, lymphovascular in-
vasion, and renal vein invasion. A predictive model was de-
veloped that included the following factors: i) ≥ 2 mitotic
figures per 10 high-power fields; ii) ≥ 70% atypical epitheli-
oid cells; iii) atypical mitotic figures; iv) necrosis. The pres-
ence of 3 or more of these factors was highly predictive of
malignant behaviour [6]. Moreover, the evaluation of an-
other series of 41 EAML patients identified a number of
clinico-pathologic parameters that also predicted for worse
outcome including: i) tuberous sclerosis complex (TSC) or
concurrent AML; ii) necrosis; iii) tumor size> 7 cm, iv)
extra renal extension and/or vein involvement, v)
carcinoma-like growth pattern. Based on these findings the
authors suggested that EAML patients should be classified
in groups with low, intermediate and high risk of disease
progression, according to the presence of 0–1, 2–3 or 4–5
of these parameters, respectively [7].
Approximately 80% of AML are sporadic while 20% de-
velop within the TSC [8]. AML tumors in the context of
TSC present bi-allelic inactivating mutations in TSC1 or
TSC2. These genes encode the proteins hamartin and
tuberin responsible for the inhibition of the mammalian
target of rapamycin (mTOR), a conserved protein kinase
that regulates cell growth and metabolism in response to
growth factors and nutrients [9]. Rapamycin and its ana-
logs, sirolimus, everolimus and temsirolimus, inhibit
mTOR pathway and are anti-tumor drugs used for meta-
static renal cell carcinoma, pancreatic neuroendocrine tu-
mors and advanced breast cancer. In addition, everolimus
has shown significant efficacy to treat TSC neoplasms, in-
cluding AML [10]. Significant clinical response to mTOR
inhibitors has been described in patients with unresectable
or recurrent PEComas, although specific data regarding
EAML is scarce [11, 12]. Whenever possible, treatment of
EAML should be surgery. Chemotherapy has limited
benefit, while response to mTOR inhibitors, awaiting
clinical trials, remains undetermined with only isolated
cases reported in the literature with contradictory outcomes
[13–16].
In this study we performed a genomic and immuno-
histochemical characterization of an EAML patient that
after developing hepatic and bone metastasis had a
complete response to sirolimus, and 36 months after the
start of treatment remains disease-free. The molecular
mechanism responsible for this extraordinary response
to sirolimus was identified by next generation sequen-
cing (NGS) and immunohistochemistry (IHC).
Case presentation
We report the case of a Caucasian male patient aged 34
without an irrelevant past medical history that presented
with unexplained weight loss. Imaging studies revealed
the presence of a left renal mass of 10 × 12 cm (Fig. 1a-b).
The patient underwent a left radical nephrectomy and the
pathology was consistent with an EAML (Fig. 2a) with
poor prognosis features (size > 7 cm, vascular and renal
sinus invasion, necrosis, and severe atypia). Immunohisto-
chemical profile revealed diffuse and intense expression of
HMB-45 and Melan A (Fig. 2b-c), along with expression
of smooth muscle actin and CD68 (KP-1, Ventana), and
negativity for CD-31, CEA, CK-pan, desmin, EMA, Ki-67,
myogenin and S-100. After nephrectomy the patient did
not receive adjuvant therapy and started follow up in ur-
ology clinics. Seven months after primary surgery the pa-
tient developed 3 liver metastases (two in segment VIII of
6 cm and 1.5 cm, respectively, and one in segment IV of
2 cm). All these lesions were completely resected through
a right partial hepatectomy with extension to segment IV
through a split in situ technique. Again, adjuvant therapy
was not administered. Five months later a new single me-
tastasis developed in the first lumbar vertebrae, and was
managed through a total L1 corpectomy. Six months after
the spine surgery liver recurrence was observed, surgical
resection was incomplete leaving positive margins and
within 12 weeks a new liver lesion of 1.7 cm was detected.
A new surgical attempt was considered not feasible and
after reviewing the scarce existing literature, it was de-
cided to start systemic treatment with sirolimus 6 mg/day
[13]. After starting sirolimus treatment the patient pre-
sented a very unusual and favorable response (complete
response after 13 months of treatment; Fig. 1c-d). Toler-
ance was excellent with grade 1 intermittent diarrhea and
acne along with grade 1 hypophosphatemia. At the time
of publication, after 36 months of treatment and about
five years of the initial diagnosis, the patient remains free
of disease and with an excellent performance status. Gen-
etic testing was performed and ruled out TSC (no TSC1
or TSC2 germline mutations detected).
Targeted NGS of MTOR,TSC1 and TSC2 genes was per-
formed on DNA extracted from formalin-fixed paraffin-
embedded primary tumor and hepatic metastasis, and the
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patient’s peripheral blood (TruSeq Custom Amplicon Low
Input; Illumina). Primary tumor failed NGS due to poor
DNA quality, however, the liver metastasis and the blood
were successfully sequenced by NGS, with a mean coverage
of 184× and 1643×, respectively, and single nucleotide vari-
ants and indels were identified. One TSC2 variant resulting
in a premature stop codon (c.2739dup; p.K914*) was found
in heterozygosity in the metastasis while it was absent in
blood (Fig. 3a-b). Sanger sequencing validated this finding,
and detected the TSC2 mutation also in the primary tumor
(Fig. 3c). IHC revealed absence of TSC2 expression in the
liver metastasis (Fig. 2d), in agreement with inactivation of
TSC2. Phospho-ribosomal protein S6 staining was positive
in the primary tumor and liver metastasis (Fig. 2e-f), indi-
cating activation of the mTOR pathway in the patient’s
tumors.
Discussion and conclusions
mTOR signaling pathway is up-regulated in many can-
cers and hamartoma syndromes through mutations in
genes that participate in this pathway. Genetic events in-
clude activating mutations in MTOR and PIK3CA and
inactivating mutations in TSC1, TSC2 and PTEN. Extra-




Fig. 1 Computed tomographic (CT) scans. Left renal mass of 10 × 12 cm at diagnosis (a and b). Liver recurrence (c) and response after 5 months
of sirolimus treatment (d)
a b c
d e f
Fig. 2 Immunohistochemical study. Hematoxylin and eosin staining of the EAML primary tumor (a). Representative images for HMB-45 (b; × 10) and Melan
A (c; × 10). TSC2 staining (Cell Signalling 4308) of the tumor metastasis, where tumor cells are negative for TSC2 while normal hepatocytes (indicated with
an arrow and “N”) show high intensity. (d; 10×). Phospho-ribosomal protein S6 (S235/S236; Cell Signaling 2211) expression in the primary tumor (e; × 40)
and liver metastasis (f; × 10)
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have been described in patients with metastatic bladder
cancer [17, 18], and in an anaplastic thyroid cancer
patient [19]. In these cases, mutations in TSC1, TSC2 or
MTOR were identified as the mechanism leading to the
drug sensitivity. However, a recent study in renal cell
carcinoma showed that some patients with mutations
activating mTOR pathway did not respond to mTOR
inhibitors, while some without mutations did [20],
suggesting that tumor specific mechanisms may be
modulating response. Thus, further investigation and
cases with extraordinary responses are required to
understand the mechanisms responsible for the sensitivity
to mTOR inhibitors.
Genetic studies have shown that AML occur due to bi-
allelic inactivation of either TSC2 or TSC1 [21]. In the case
of TSC AML it is caused by a germline mutation in either of
these genes plus a tumor second hit, while sporadic AML is
almost exclusively caused by mutations in TSC2 [22, 23]. In
both cases hyperactivation of mTORC1 occurs, leading to
tumor development. In EAML, similarly to AML,TSC2 gene
deletions seem to be frequent [24], however, studies are
scarce. The EAML patient presented here is a sporadic case
with a novel TSC2 mutation (c.2739dup, p.K914*), not de-
scribed previously in COSMIC or in the germline TCS2 Lei-
den Open Variation Database (LOVD). However, the LOVD
includes a sporadic TSC patient with a TSC2 protein trun-
cated at Threonine 913 (c.2737_2738delAC), allowing to
classify this novel variant as pathogenic. Inactivation of TSC2
and over-activation of mTORC1 in the tumor cells were
confirmed by IHC, and were in agreement with the extraor-
dinary response to sirolimus.
Previous studies have reported mTOR pathway activa-
tion for TSC1/TSC2 mutations in sporadic AML and
PEComas [25–27], suggesting that mTOR inhibition could
potentially provide a therapeutic benefit. A double-blind,
placebo-controlled, phase 3 trial tested the efficacy of the
mTOR inhibitor everolimus in patients with AML associ-
ated with TSC or sporadic lymphangioleiomyomatosis.
The study showed that everolimus was superior to placebo
and reduced significantly AML volume with an acceptable
safety profile, in 2012 this drug was approved for the treat-
ment of adults with renal AML associated with TSC who
do not require immediate surgery [28].
However, therapeutic experience with aggressive EAML
is scarce. There are only about a dozen published cases in
the literature in which EAML patients received mTOR in-
hibitors with variable outcomes. These reports consist on
clinical descriptions that include favorable responses, in
most of the cases with no genetic study associated [13, 14,
29–31]. Additionally, other publications have reported un-
satisfactory responses to mTOR inhibition [15, 16], sug-
gesting differences in the driver pathways of these tumors.
In summary, only a few cases of EAML with benefit
from mTOR inhibitors have been reported, and the
mechanisms underlying these responses are unexplored.
This study reveals TSC2 deficiency in a sporadic EAML
patient as the mutation causative of an exceptional
response to sirolimus. These results support NGS as
a useful tool to predict sensitivity to mTOR inhibitors
in patients with EAML, this rare and potentially
aggressive urological malignancy is misrepresented in
clinical trials.
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Fig. 3 Tumor TSC2 point mutation. Targeted NGS revealed one
frameshift mutation in TSC2 gene (c.2739dup; p.K914*) absent in the
patient’s blood (a) and present in the liver metastasis (b). The
primary tumor DNA failed NGS technique, but Sanger sequencing
detected the TSC2 mutation (c). Representative genome images
from the Integrative Genomics Viewer (Broad Institute) are shown
together with Sanger chromatograms
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